Julia C Radosa1,2, Anne Eaton3, Michelle Stempel1, Amrin Khander1, Cornelia Liedtke4, Erich-Franz Solomayer2, Maria Karsten1, Melissa Pilewskie1, Monica Morrow1, Tari A King5,6. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany. 3. Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Gynecology and Obstetrics, University of Schleswig-Holstein, Lübeck, Germany. 5. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tking7@partners.org. 6. Breast Surgery, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. tking7@partners.org.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) subtype and young patient age are both associated with an increased risk of local recurrence (LR) and distant recurrence (DR). In young women with TNBC, it is unclear whether subtype or patient age is driving prognosis. METHODS: Patients treated for primary TNBC from 1998 to 2011 were identified from the breast surgery database. Clinicopathologic characteristics, treatment, and outcomes were compared between patients <40 and ≥40 years of age at diagnosis. Multivariate models were used to identify factors independently associated with LR and DR. RESULTS: Among 1930 patients with TNBC, 289 (15 %) were <40 and 1641 (85 %) were ≥40 years of age at diagnosis. Younger patients were more likely to present with higher stage disease and more likely to receive mastectomy (p < 0.01), axillary node dissection (p < 0.01), and chemotherapy (p < 0.01). At a median follow-up of 74 (0-201.1) months, there was no difference in LR or disease-free survival (DFS) by age group [5-year LR = 3.9 % (95 % confidence interval (CI) 1.5-6.2) vs. 4.5 % (95 % CI 3.5-5.6) and 5-year DFS = 75.3 % (95 % CI 70.2-80.7) vs. 77.7 % (95 % CI 75.6-79.8), p = 0.94] in patients aged <40 and ≥40 years, respectively. On multivariate analysis, larger tumor size, lymphovascular invasion, and nodal positivity were associated with increased risk of DR. Age and type of surgery were not significantly associated with either outcome. CONCLUSIONS: Young age at diagnosis is not an independent risk factor for LR or DR in patients with TNBC.
BACKGROUND: Triple-negative breast cancer (TNBC) subtype and young patient age are both associated with an increased risk of local recurrence (LR) and distant recurrence (DR). In young women with TNBC, it is unclear whether subtype or patient age is driving prognosis. METHODS:Patients treated for primary TNBC from 1998 to 2011 were identified from the breast surgery database. Clinicopathologic characteristics, treatment, and outcomes were compared between patients <40 and ≥40 years of age at diagnosis. Multivariate models were used to identify factors independently associated with LR and DR. RESULTS: Among 1930 patients with TNBC, 289 (15 %) were <40 and 1641 (85 %) were ≥40 years of age at diagnosis. Younger patients were more likely to present with higher stage disease and more likely to receive mastectomy (p < 0.01), axillary node dissection (p < 0.01), and chemotherapy (p < 0.01). At a median follow-up of 74 (0-201.1) months, there was no difference in LR or disease-free survival (DFS) by age group [5-year LR = 3.9 % (95 % confidence interval (CI) 1.5-6.2) vs. 4.5 % (95 % CI 3.5-5.6) and 5-year DFS = 75.3 % (95 % CI 70.2-80.7) vs. 77.7 % (95 % CI 75.6-79.8), p = 0.94] in patients aged <40 and ≥40 years, respectively. On multivariate analysis, larger tumor size, lymphovascular invasion, and nodal positivity were associated with increased risk of DR. Age and type of surgery were not significantly associated with either outcome. CONCLUSIONS: Young age at diagnosis is not an independent risk factor for LR or DR in patients with TNBC.
Authors: Emilia Montagna; Patrick Maisonneuve; Nicole Rotmensz; Giuseppe Cancello; Monica Iorfida; Alessandra Balduzzi; Viviana Galimberti; Paolo Veronesi; Alberto Luini; Giancarlo Pruneri; Luca Bottiglieri; Mauro G Mastropasqua; Aron Goldhirsch; Giuseppe Viale; Marco Colleoni Journal: Clin Breast Cancer Date: 2012-10-24 Impact factor: 3.225
Authors: Trevor D Thompson; Lori A Pollack; Christopher J Johnson; Xiao-Cheng Wu; Judy R Rees; Mei-Chin Hsieh; Randi Rycroft; MaryBeth Culp; Reda Wilson; Manxia Wu; Kevin Zhang; Vicki Benard Journal: Cancer Epidemiol Date: 2020-01-06 Impact factor: 2.984
Authors: V Zenzola; M A Cabezas-Quintario; M Arguelles; E Pérez-Fernández; Y Izarzugaza; A Correa; J García-Foncillas Journal: Clin Transl Oncol Date: 2018-04-18 Impact factor: 3.405
Authors: Mattias Aine; Ceren Boyaci; Johan Hartman; Jari Häkkinen; Shamik Mitra; Ana Bosch Campos; Emma Nimeus; Anna Ehinger; Johan Vallon-Christersson; Åke Borg; Johan Staaf Journal: Breast Cancer Res Date: 2021-02-10 Impact factor: 6.466